Business Context and Reporting Period
Company: Anbio Biotechnology (Cayman Islands)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Anbio Biotechnology is a medical device company focused on in vitro diagnostics (IVD). It designs IVD products and outsources manufacturing to third-party suppliers. The company operates primarily through its subsidiary, Anbio Samoa. Its product portfolio includes lateral flow immunoassays (LFIA), fluorescence immunoassays (FIA), and molecular diagnostic solutions for infectious diseases, cancer, and cardiovascular conditions.
Recent Capital Event: On February 20, 2025, the company completed an Initial Public Offering (IPO) of 1,600,000 Class A Ordinary Shares at $5.00 per share, raising gross proceeds of $8.0 million and net proceeds of approximately $7.23 million.
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $8,646,844 | $8,185,146 | $6,711,990 |
| Gross Profit | $7,543,162 | $5,885,384 | $3,360,869 |
| Gross Margin | 87.2% | 71.9% | 50.1% |
| Net Income | $6,403,463 | $2,372,842 | $2,253,709 |
| Operating Expenses | $1,775,422 | $3,890,017 | $1,399,940 |
| Cash and Cash Equivalents (Year End) | $7,766,738 | $11,760,859 | $9,687,976 |
| Working Capital | $30,155,023 | $16,804,110 | N/A |
| Debt | $0 | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5.6% year-over-year (YoY) to $8.65 million. This growth was driven by increased demand for customized products and non-COVID IVD products, offsetting a decline in COVID-19 related sales.
- Margin Expansion: Gross margin improved significantly to 87.2% from 71.9% in 2024. This was attributed to a strategic shift toward higher-margin products and better procurement cost control.
- Expense Reduction: Operating expenses decreased by 54.2% to $1.78 million. Selling, general, and administrative (SG&A) expenses dropped by $1.86 million, primarily due to the completion of IPO-related professional fees incurred in 2024.
- Profitability Surge: Net income increased by 169.9% to $6.40 million, driven by the combination of higher gross margins and significantly lower operating expenses.
- Product Mix Shift: Revenue from COVID-19 related products dropped to 19.6% of total revenue in 2025, down from 54% in 2024 and 60% in 2023. Non-COVID products now represent 80.4% of revenue.
- Cash Flow: Net cash used in operating activities was $6.74 million in 2025, a reversal from the $2.08 million provided in 2024. This was primarily due to a significant increase in prepayments ($8.4 million) and accounts receivable ($2.6 million), despite strong net income.
Guidance, Outlook, and Risks
Outlook and Strategy: Management plans to utilize IPO proceeds and operating cash flows to fund operations for at least the next 12 months. The strategy focuses on diversifying the product portfolio (including veterinary diagnostics and dry chemistry) and expanding into new geographic markets (Americas, APAC, Africa) to reduce reliance on the EU and pandemic-related products.
Regulatory Risks (IVDR): All current products are CE marked under the older IVDD directive. The company must transition to the new In Vitro Diagnostic Regulation (IVDR) by specific deadlines (ranging from 2027 to 2029 depending on risk class). Failure to secure IVDR registration could halt sales in the EU, which currently accounts for 60% of revenue.
Concentration Risks:
- Customers: Two customers accounted for 47% of total revenue in 2025. One customer accounted for 82% of accounts receivable.
- Suppliers: Two suppliers accounted for 100% of total purchases in 2025. The company relies entirely on third-party manufacturers.
Corporate Governance: The company has a dual-class share structure. Class B shares (held by CVC Investment and Northwestern Investment) carry 50 votes per share, giving these entities 99.22% of the total voting power despite holding a minority of the economic interest.
Investor Verification Checklist
- Customer Concentration: Verify the stability of contracts with the top two customers who generated 47% of 2025 revenue.
- Supplier Dependency: Assess the risk of supply chain disruption given reliance on only two suppliers for 100% of purchases.
- IVDR Compliance Timeline: Confirm the status of technical documentation and Notified Body partnerships required for EU market access post-2027.
- Accounts Receivable Quality: Investigate the collectability of the 82% of receivables owed by a single customer.
- Prepayment Utilization: Review the nature of the $14.1 million in prepayments (up $8.4 million YoY) to ensure they represent valid inventory or services to be received.
- Control Structure: Understand the implications of the dual-class voting structure where founders control 99% of voting rights.